Peer-Reviewed Publication
JCO Precis Oncol2026;10(7):e2600321.July 1, 2026Journal Article
Development and Validation of a Computational Histology Artificial Intelligence-Powered Biomarker in Metastatic Hormone-Sensitive Prostate Cancer on Randomized Phase III Trials.
Christopher J Sweeney1, Vrishab Krishna2, Viswesh Krishna2, Akshay Neema2, Asit Tarsode2, Vinod V Subhash3, Lisa G Horvath4, James G Kench5, Martin R Stockler6, Sonia Yip6, Hayley Thomas6, Umang Swami7, Haochen Zhang2, Snehal Sonawane2,8, Waleed M Abuzeid2,9, Vivek Nimgaonkar2,10, Ekin Tiu2, Drew Watson11, Lesli Kiedrowski2, Trevor J Royce2,12, David D Yang13, Phuoc T Tran14, Charles J Ryan15, Paul L Nguyen13, Alicia K Morgans16, Anirudh Joshi2, Neeraj Agarwal7, Ian D Davis3,17,18
1South Australian Immunogenomics Cancer Institute, Adelaide University, Adelaide, Australia.
2Valar Labs, Palo Alto, CA.
3ANZUP Cancer Trials Group, Sydney, Australia.
4Chris O'Brien Lifehouse, Sydney, Australia.
5Department of Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Royal Prince Alfred Hospital, Camperdown, Australia.
6NHMRC Clinical Trials Centre, The University of Sydney, Sydney, Australia.
7Department of Medicine, University of Utah, Salt Lake City, UT.
8University of Illinois at Chicago, Chicago, IL.
9University of Washington, Seattle, WA.
10Johns Hopkins University, Baltimore, MD.
11Watson Consulting, Palo Alto, CA.
12Department of Radiation Oncology, Wake Forest School of Medicine, Winston-Salem, NC.
13Department of Radiation Oncology, Mass General Brigham, Boston, MA.
14Department of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
15Memorial Sloan Kettering Cancer Center, New York, NY.
16Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA.
17Eastern Health Clinical School, Monash University, Melbourne, Australia.
18Cancer Services, Eastern Health, Melbourne, Australia.
Abstract
PURPOSE: Metastatic hormone-sensitive prostate cancer (mHSPC) is a heterogeneous disease state with multiple treatment options. Biomarkers are needed for risk stratification and to guide treatment intensification or deintensification. We used a computational histology artificial intelligence-based platform (CHAI) to develop and validate a digital image-only prognostic biomarker in mHSPC with parti…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans